trial

Pharmacokinetics, Safety and Tolerability Study of PF-03463275 in Healthy Male Japanese and Western Subjects

NCTId NCT01159626
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1 · Completed
Enrollment 40 (actual)
Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Primary completion 2010-11
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1
Status
Completed
Enrollment
40 (actual)
Study type
Interventional
Allocation
Randomized
Model
Crossover
Masking
Double
Start
2010-07
Primary completion
2010-11
Eligibility
MALE · 18 Years · 55 Years

Interventions & indications

Drugs
PF-03463275

Sponsors

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.Lead Sponsor

Sites

1 total
Glendale, United States

Facts & assertions

4 sourced
Enrollment
40
Phase
PHASE1
Primary Completion Date
2010-11
Status
COMPLETED
relationships
The graph out of here
drug
PF-03463275
drug
lead_sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
company
indication
Healthy
indication
Schizophrenia
indication